🇺🇸 Haemophilus Influenza type b vaccine in United States

20 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 2 reports (10%)
  2. Diarrhoea — 2 reports (10%)
  3. Diarrhoea Haemorrhagic — 2 reports (10%)
  4. Drug Ineffective — 2 reports (10%)
  5. Enterocolitis — 2 reports (10%)
  6. Faecal Calprotectin Abnormal — 2 reports (10%)
  7. Gastritis — 2 reports (10%)
  8. General Physical Health Deterioration — 2 reports (10%)
  9. Helicobacter Infection — 2 reports (10%)
  10. Neck Pain — 2 reports (10%)

Source database →

Haemophilus Influenza type b vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Haemophilus Influenza type b vaccine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Haemophilus Influenza type b vaccine in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.